9. Références bibliographiques

  1. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/346387, accessed 1 December 2021).
  2. Marais B. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402.
  3. Martinez L, Cords O, Horsburgh CR, Andrews JR, Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973-84.
  4. Snow KJ, Sismanidis C, Denholm J, Sawyer SM, Graham SM. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 2018;51:1702352.
  5. Le programme de développement durable. [site web] https://www.un.org/sustainabledevelopment/fr/
    development-agenda/, page consultée le 25 mai 2022.
  6. The END TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization; 2014 (https://www.who.int/tb/strategy/End_TB_Strategy.pdf, accessed 1 December 2021).
  7. Political declaration of the UN General Assembly High-Level Meeting on the Fight Against Tuberculosis, 26 September 2018. New York: United Nations; 2019 (https://www.who.int/docs/default-source/documents/ tuberculosis/political-declaration-un-general-assembly-tb-tuberculosis.pdf?sfvrsn=4f4090dc_1&downloa d=true, accessed 1 December 2021).
  8. Lignes directrices concernant la prise en charge de la tuberculose chez l’enfant dans le cadre des programmes nationaux de lutte contre la tuberculose (deuxième édition). Genève, Organisation mondiale de la Santé,
    2016 (https://apps.who.int/iris/handle/10665/251469, page consultée le 25 mai 2022).
  9. Lignes directrices unifiées de l’OMS sur la tuberculose. Module 4 : traitement – traitement de la tuberculose pharmacorésistante. Genève, Organisation mondiale de la Santé, 2020 (https://apps.who.int/iris/
    handle/10665/340191, page consultée le 25 mai 2022).
  10. Feuille de route pour mettre fin à la tuberculose de l’enfant et de l’adolescent, deuxième édition. Genève, Organisation mondiale de la Santé, 2019 (https://apps.who.int/iris/handle/10665/324867, page consultée
    le 25 mai 2022).
  11. Lignes directrices unifiées de l’OMS sur la tuberculose. Module 2 : Dépistage – Dépistage systématique de la tuberculose. Genève, Organisation mondiale de la Santé, 2022 (https://apps.who.int/iris/
    handle/10665/353406, page consultée le 25 mai 2022).
  12. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/311259, accessed 1 December 2021).
  13. BCG vaccines: WHO position paper - February 2018. Weekly Epidemiological Record. 2018;93(8):73-96.
  14. WHO consolidated guidelines on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331170, accessed 1 December 2021).
  15. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5(9):e898-e906.
  16. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342331, accessed 1 December 2021).
  17. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/handle/10665/44652, accessed 1 December 2021).
  18. Kay AW, Gonzalez Fernandez L, Takwoingi Y, Eisenhut M, Detjen AK, Steingart KR, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020;8:CD013359.
  19. Jaganath D, Wambi P Reza TF, Nakafeero J, Aben EO, Kiconco E, et al. A prospective evaluation of Xpert MTB/RIF Ultra for childhood pulmonary tuberculosis in Uganda. J Pediatric Infect Dis Soc. 2021;10(5):586-92.
  20. Liu XH, Xia L, Song B, Wang H, Qian XQ, Wei JH, et al. Stool-based Xpert MTB/RIF Ultra assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: A prospective cohort study. J Infect. 2021;82(1):84-9.
  21. Parigi S, Venturini E, Galli L, Chiappini E. Xpert(®) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates. Int J Tuberc Lung Dis. 2021;25(1):75-7.
  22. Ssengooba W, Iragena JD, Nakiyingi L, Mujumbi S, Wobudeya E, Mboizi R, et al. Accuracy of Xpert Ultra in diagnosis of pulmonary tuberculosis among children in Uganda: a substudy from the SHINE trial. J Clin Microbiol. 2020;58(9): e00410-20.
  23. Validation of a tuberculosis treatment decision algorithm in HIV-infected children (TB-Speed HIV). Paris: Institut National de la Sante Et de la Recherche Medicale; 2021 (https://clinicaltrials.gov/show/NCT04121026, accessed 1 December 2021).
  24. Development of a diagnostic prediction score for tuberculosis in hospitalized children with severe acute malnutrition (TB-Speed SAM). Paris: Institut National de la Sante Et de la Recherche Medicale; 2021 (https:// clinicaltrials.gov/show/NCT04240990, accessed 1 December 2021).
  25. Stool Processing Kit (SPK) evaluation for paediatric TB. Switzerland: Foundation for Innovative New Diagnostics; 2021 (https://clinicaltrials.gov/ct2/show/NCT04899076 accessed 22 February 2022).
  26. Kabir S, Rahman SMM, Ahmed S, Islam MS, Banu RS, Shewade HD, et al. Xpert Ultra assay on stool to diagnose pulmonary tuberculosis in children. Clin Infect Dis. 2021;73(2):226-34.
  27. Evaluation of four stool processing methods combined with Xpert MTB/RIF Ultra for diagnosis of intrathoracic paediatric TB (TB-Speed - stool processing). Paris: Institut National de la Sante Et de la Recherche Medicale; 2021 (https://clinicaltrials.gov/ct2/show/NCT04203628 accessed 1 December 2021).
  28. TB-Speed stool processing - instructions for use - sucrose flotation method. Paris: University of Bordeaux; 2020 (https://www.tb-speed.com/wp-content/uploads/2020/09/TB-Speed_Stools_Standard_Operating_ Procedures.pdf, accessed 1 December 2021).
  29. Simple One Step (SOS) stool processing method and Xpert MTB/RIF (Ultra) testing for the detection of Mycobacterium tuberculosis complex and rifampicin resistance. The Hague: KNCV Tuberculosis Foundation; 2021 (https://www.kncvtbc.org/uploaded/2021/03/Stoolbox-SOP1.pdf, accessed 1 December 2021).
  30. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detention, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342369, accessed 1 December 2021).
  31. Graham SM, Cuevas LE, Jean-Philippe P Browning R, Casenghi M, Detjen AK, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. Clin Infect Dis. 2015;61Suppl 3:S179-87.
  32. Guide de L’Union pour le diagnostic et la prise en charge de la tuberculose chez l’enfant. Troisième édition, 2016. Paris, Union Internationale Contre la Tuberculose et les Maladies Respiratoires, 2016 (https://theunion.
    org/sites/default/files/2020-08/Desk-Guide_FR_2016Web3.pdf, page consultée le 25 mai 2022).
  33. Aurilio RB, Luiz RR, Land MGP Cardoso CAA, Kritski AL, Sant'Anna CC. The clinical and molecular diagnosis of childhood and adolescent pulmonary tuberculosis in referral centers. Rev Soc Bras Med Trop. 2020;53 (http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100351&nrm=iso, accessed 1 December 2021).
  34. Song R, Click ES, McCarthy KD, Heilig CM, McHembere W, Smith JP et al. Sensitive and feasible specimen collection and testing strategies for diagnosing tuberculosis in young children. JAMA Pediatr. 2021;175(5):e206069 (https://www.ncbi.nlm.nih.gov/pubmed/33616611, accessed 1 December 2021).
  35. Lopez-Varela E, Augusto OJ, Gondo K, Garcia-Basteiro AL, Fraile O, Ira T, et al. Incidence of tuberculosis among young children in rural Mozambique. Pediatr Infect Dis J. 2015;34(7):686-92.
  36. Myo K, Zaw M, Swe TL, Kyaw YY, Thwin T, Myo TT, et al. Evaluation of Xpert® MTB/RIF assay as a diagnostic test for pulmonary tuberculosis in children in Myanmar. Int J Tuberc Lung Dis. 2018;22(9):1051-5.
  37. Marcy O, Ung V, Goyet S, Borand L, Msellati P Tejiokem M, et al. Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children. Clin Infect Dis. 2016;62(9):1161-8.
  38. Hamid M, Brooks MB, Madhani F, Ali H, Naseer MJ, The Childhood Tuberculosis Karachi Group, et al. Risk factors for unsuccessful tuberculosis treatment outcomes in children. PLoS ONE. 2019;14(9):e0222776 (https://doi.org/10.1371/journal.pone.0222776, accessed 1 December 2021).
  39. Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, et al. Mycobacterium tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. BMC Res Notes. 2019;12(1):349.
  40. 40. Mesman AW, Soto M, Coit J, Calderon R, Aliaga J, Pollock NR, et al. Detection of Mycobacterium tuberculosis in pediatric stool samples using TruTip technology. BMC Infect Dis. 2019;19(1):563.
  41. Tafur KT, Coit J, Leon SR, Pinedo C, Chiang SS, Contreras C, et al. Feasibility of the string test for tuberculosis diagnosis in children between 4 and 14 years old. BMC Infect Dis. 2018;18(1):574.
  42. Walters E, Demers AM, van der Zalm MM, Whitelaw A, Palmer M, Bosch C, et al. Stool culture for diagnosis of pulmonary tuberculosis in children. J Clin Microbiol. 2017;55(12):3355-65.
  43. Walters E, Scott L, Nabeta P Demers AM, Reubenson G, Bosch C, et al. Molecular detection of Mycobacterium tuberculosis from stools in young children by use of a novel centrifugation-free processing method. J Clin Microbiol. 2018;56(9): e00781-18.
  44. Walters E, van der Zalm MM, Palmer M, Bosch C, Demers A-M, Draper H, et al. Xpert MTB/RIF on stool is useful for the rapid diagnosis of tuberculosis in young children with severe pulmonary disease. Pediatr Infect Dis J. 2017;36(9):837-43.
  45. Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S, et al. Accuracy of Xpert MTB/RIF ultra for the diagnosis of pulmonary tuberculosis in children. Pediatr Infect Dis J. 2018;37(10): e261-e263.
  46. Orikiriza P Nansumba M, Nyehangane D, Bastard M, Mugisha IT, Nansera D, et al. Xpert MTB/RIF diagnosis of childhood tuberculosis from sputum and stool samples in a high TB-HIV-prevalent setting. Eur J Clin Microbiol Infect Dis. 2018;37(8):1465-73.
  47. Giang do C, Duong TN, Ha DT, Nhan HT, Wolbers M, Nhu NT, et al. Prospective evaluation of GeneXpert for the diagnosis of HIV- negative pediatric TB cases. BMC Infect Dis. 2015;15:70.
  48. Zawedde-Muyanja S, Nakanwagi A, Dongo JP Sekadde MP Nyinoburyo R, Ssentongo G, et al. Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda. Int J Tuberc Lung Dis. 2018;22(11):1314-21.
  49. Manual de recomendagoes para o controle da tuberculose no Brasil. Brasilia: Ministerio da Saude; 2019 (https://bvsms.saude.gov.br/bvs/publicacoes/manual_recomendacoes_controle_tuberculose_brasil_2_ed.pdf, accessed 30 November 2021).
  50. Gunasekera KS, Walters E, van der Zalm MM, Palmer M, Warren JL, Hesseling AC, et al. Development of a treatment-decision algorithm for HIV-uninfected children evaluated for pulmonary tuberculosis. Clin Infect Dis. 2021;73(4):e904-e12.
  51. Edwards K. The diagnosis of childhood tuberculosis. P N G Med J. 1987;30(2):169-78.
  52. Marcy O, Borand L, Ung V, Msellati P Tejiokem M, Huu KT, et al. A treatment-decision score for HIV-infected children with suspected tuberculosis. Pediatrics. 2019;144(3):e20182065.
  53. Montenegro SH, Gilman RH, Sheen P Cama R, Caviedes L, Hopper T, et al. Improved detection of Mycobacterium tuberculosis in Peruvian children by use of a heminested IS6110 polymerase chain reaction assay. Clin Infect Dis. 2003;36(1):16-23.
  54. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics. 2006;118(5):e1350-9.
  55. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022.
  56. Rapid advice: treatment of tuberculosis in children. Geneva: World Health Organization; 2010 (https://apps. who.int/iris/handle/10665/44444, accessed 23 February 2022).
  57. Turkova A, Wills GA, Wobudeya E, Chabala C, Palmer M, Kinikar A, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med. 2022;386(7).
  58. 58. Chabala C, Turkova A, Thomason MJ, Wobudeya E, Hissar S, Mave V, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials 2018;19(1):237 (https://doi.org/10.1186/s13063-018-2608-5, accessed 23 February 2022).
  59. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007 (https://apps.who. int/iris/handle/10665/43699, accessed 6 December 2021).
  60. Lignes directrices : mises à jour de la prise en charge de la malnutrition aiguë sévère chez le nourrisson et chez l’enfant. Genève, Organisation mondiale de la Santé, 2015 (https://apps.who.int/iris/handle/10665/162815,
    page consultée le 25 mai 2022).
  61. Manuel opérationnel de l’OMS sur la tuberculose. Module 4 : traitement – traitement de la tuberculose pharmacorésistante. Genève, Organisation mondiale de la Santé, 2021 (https://apps.who.int/iris/
    handle/10665/340189, page consultée le 25 mai 2022).
  62. Schaaf HS, Marais BJ, Whitelaw A, Hesseling AC, Eley B, Hussey GD, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis. 2007;7(1):140 (https://doi.org/10.1186/1471-2334-7-140, accessed 6 December 2021).
  63. Wolzak NK, Cooke ML, Orth H, van Toorn R. The changing profile of pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr. 2012;58(6):491-5.
  64. Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):947-57.
  65. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis (Edinb).2010; 90(6):375-92.
  66. Guidelines for the management of tuberculosis in children. Pretoria, South Africa: Department of Health; 2013.
  67. van Toorn R, Schaaf HS, Laubscher JA, van Elsland SL, Donald PR, Schoeman JF. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33(3):248-52.
  68. van Well GT, Paes BF, Terwee CB, Springer P Roord JJ, Donald PR, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123(1):e1-8.
  69. Bang ND, Caws M, Truc TT, Duong TN, Dung NH, Ha DTM, et al. Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study. BMC Infect Dis. 2016;16(1):573.
  70. Solomons R. Developmental outcome at treatment completion in South African children with tuberculous meningitis. 2015.
  71. Dhawan SR, Gupta A, Singhi P Sankhyan N, Malhi P Khandelwal N. Predictors of neurological outcome of tuberculous meningitis in childhood: a prospective cohort study from a developing country. J Child Neurol. 2016;31(14):1622-7.
  72. Gupta R, Kushwaha S, Thakur R, Jalan N, Rawat P Gupta P et al. Predictors of adverse outcome in patients of tuberculous meningitis in a multi-centric study from India. Indian J Tuberc. 2017;64(4):296-301.
  73. Thee S, Basu RR, Blazquez-Gamero D, Falcon-Neyra L, Neth O, Noguera-Julian A, et al. Treatment and outcome in children with tuberculous meningitis - a multi-centre Paediatric Tuberculosis Network European Trials Group study. Clin Infect Dis. 2021; ciab982 (doi: 10.1093/cid/ciab982, accessed 23 February 2022).
  74. Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, Fairlie L, van der Laan LE, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother. 2021; 76(12):3237-46.
  75. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16(10):1193-1201.
  76. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Perez-Velez CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383(9928):1572-9.
  77. Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis.2018;22(5):3-6.
  78. Global tuberculosis report 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/ handle/10665/336069, accessed 1 December 2021).
  79. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e1002591 (https://journals.plos.org/plosmedicine/article?id=10.1371/journal. pmed.1002591, accessed 23 February 2022).
  80. Prescribing information. Sirturo (bedaquiline) product insert. Silver Spring: Food and Drug Administration (https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf, accessed 1 December 2021).
  81. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/84879, accessed 1 December 2021).
  82. Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis, A review of available evidence (2016). Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/254712, accessed 1 December 2021).
  83. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/311389, accessed 1 December 2021).
  84. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Online annexes. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/332678, accessed 1 December 2021).
  85. Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, et al. Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. Br J Clin Pharmacol. 2018; 84(10):2384-92.
  86. Wiseman CA, Gie RP Starke JR, Schaaf HS, Donald PR, Cotton MF et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 2012;31(4):347-52.
  87. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/341981, accessed 1 December 2021).
  88. Model List of Essential Medicines for Children - 8th List (2021). Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/345534, accessed 1 December 2021).
  89. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/204465, accessed 1 December 2021).
  90. Deltyba: EPAR - Product Information. Amsterdam: European Medicines Agency; 2014 (https://www.ema. europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf, accessed 1 December 2021).
  91. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/137334, accessed 1 December 2021).
  92. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/250614, accessed 1 December 2021).
  93. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/250125, accessed 1 December 2021).
  94. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/130918, accessed 1 December 2021).
  95. A5343. A trial of the safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, among participants taking multidrug treatment for drug-resistant pulmonary tuberculosis. A limited-center trial of the AIDS Clinical Trials Group (ACTG). Rockville: National Institute of Allergy and Infectious Diseases; 2018 (https://clinicaltrials.gov/ProvidedDocs/48/NCT02583048/Prot_001.pdf, accessed 1 December 2021).
  96. Consolidated guidelines on drug-resistant tuberculosis treatment, 2018 update [online annexes]. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/332678, accessed 1 December 2021).
  97. Lignes directrices pour le traitement de la tuberculose sensible aux médicaments et la prise en charge du patient, mise à jour 2017. Genève, Organisation mondiale de la Santé, 2017 (https://apps.who.int/iris/
    handle/10665/255052, page consultée le 25 mai 2022).
  98. Tuberculose de l’enfant : feuille de route : objectif zéro décès. Genève, Organisation mondiale de la Santé, 2016 (https://apps.who.int/iris/handle/10665/204379, page consultée le 25 mai 2022).
  99. Public-private mix for TB prevention and care: a roadmap. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/333885, accessed 1 December 2021).
  100. WHO consolidated guidelines on tuberculosis. Module 4: treatment - care and support during tuberculosis treatment. Geneva: World Health Organization; 2022.
  101. Talukder K, Salim MA, Jerin I, Sharmin F, Talukder MQ, Marais BJ, et al. Intervention to increase detection of childhood tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2012;16(1):70-5.
  102. Khan AJ, Khowaja S, Khan FS, Qazi F, Lotia I, Habib A, et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. Lancet Infect Dis. 2012;12(8):608-16.
  103. Malik AA, Amanullah F, Codlin AJ, Siddiqui S, Jaswal M, Ahmed JF, et al. Improving childhood tuberculosis detection and treatment through facility-based screening in rural Pakistan. Int J Tuberc Lung Dis. 2018;22(8):851-7.
  104. Maha A, Majumdar SS, Main S, Phillip W, Witari K, Schulz J, et al. The effects of decentralisation of tuberculosis services in the East New Britain Province, Papua New Guinea. Public Health Action. 2019;9(Suppl 1):S43-S49.
  105. Islam Z, Sanin KI, Ahmed T. Improving case detection of tuberculosis among children in Bangladesh: lessons learned through an implementation research. BMC Public Health. 2017;17(1):131.
  106. Catalyzing Pediatric TB Innovation (CaP-TB) project. Unpublished data. 2021.
  107. Oshi DC, Chukwu JN, Nwafor CC, Meka AO, Madichie NO, Ogbudebe CL, et al. Does intensified case finding increase tuberculosis case notification among children in resource-poor settings? A report from Nigeria. Int J Mycobacteriol. 2016;5(1):44-50.
  108. Joshi B, Chinnakali P Shrestha A, Das M, Kumar AM, Pant R, et al. Impact of intensified case-finding strategies on childhood TB case registration in Nepal. Public Health Action. 2015;5(2):93-8.
  109. Hanrahan CF, Nonyane BAS, Mmolawa L, West NS, Siwelana T, Lebina L, et al. Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB). PLoS Med. 2019;16(4):e1002796 (https://journals.plos.org/plosmedicine/article/ file?id=10.1371/journal.pmed.1002796&type=printable, accessed 23 February 2022).
  110. Moyo S, Verver S, Hawkridge A, Geiter L, Hatherill M, Workman L, et al. Tuberculosis case finding for vaccine trials in young children in high-incidence settings: a randomised trial. Int J Tuberc Lung Dis. 2012;16(2):185-91.
  111. Davis JL, Turimumahoro P, Meyer AJ, Ayakaka I, Ochom E, Ggita J, et al. Home-based tuberculosis contact investigation in Uganda: a household randomised trial. ERJ Open Res. 2019;5(3): 00112 (doi: 10.1183/23120541.00112-2019, accessed 23 February 2022).
  112. Fatima R, Qadeer E, Yaqoob A, Haq Mu, Majumdar SS, Shewade HD, et al. Extending 'contact tracing' into the community within a 50-metre radius of an index tuberculosis patient using Xpert MTB/RIF in urban, Pakistan: did it increase case detection? PLoS ONE. 2016;11(11):e0165813 (https://doi.org/10.1371/journal. pone.0165813, accessed 1 December 2021).
  113. Reddy KK, Ananthakrishnan R, Jacob AG, Das M, Isaakidis P Kumar AMV Intensified tuberculosis case finding amongst vulnerable communities in southern India. Public Health Action. 2015;5(4):246-8.
  114. Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003;7(12 Suppl 3):S501-9.
  115. Sachdeva KS, Raizada N, Sreenivas A, van't Hoog AH, van den Hof S, Dewan PK, et al. Use of Xpert MTB/ RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLoS ONE. 2015;10(5):e0126065 (https://doi.org/10.1371/journal.pone.0126065, accessed 1 December 2021).
  116. Yassin MA, Datiko DG, Tulloch O, Markos P Aschalew M, Shargie EB, et al. Innovative community-based approaches doubled tuberculosis case notification and improve treatment outcome in Southern Ethiopia. PLoS ONE. 2013;8(5):e63174 (https://doi.org/10.1371/journal.pone.0063174, accessed 1 December 2021).
  117. Zachariah R, Spielmann MP Harries AD, Gomani P Graham SM, Bakali E, et al. Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis. 2003;7(11):1033-9.
  118. Ketema L, Dememew ZG, Assefa D, Gudina T, Kassa A, Letta T, et al. Evaluating the integration of tuberculosis screening and contact investigation in tuberculosis clinics in Ethiopia: A mixed method study. PLoS ONE. 2020;15(11):e0241977 (https://doi.org/10.1371/journal.pone.0241977, accessed 23 February 2022).
  119. Miyano S, Dube C, Kayama N, Ishikawa N, Nozaki I, Syakantu G. Association between tuberculosis treatment outcomes and the mobile antiretroviral therapy programme in Zambia. Int J Tuberc Lung Dis. 2013;17(4):540-5.
  120. Wingfield T, Tovar MA, Huff D, Boccia D, Montoya R, Ramos E, et al. A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru. Bull World Health Organ. 2017;95(4):270-80.
  121. Rocha C, Montoya R, Zevallos K, Curatola A, Ynga W, Franco J, et al. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational assessment. Int J Tuberc Lung Dis. 2011;15 Suppl 2(Suppl 2):50-7.
  122. Infection tuberculeuse latente : lignes directrices unifiées et actualisées pour la prise en charge programmatique. Genève, Organisation mondiale de la Santé, 2018 (https://apps.who.int/iris/handle/10665/312054, page
    consultée le 25 mai 2022).
  123. Updated recommendations on service delivery for the treatment and care of people living with HIV Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/341052, accessed 23 February 2022).
  124. Politique de l’OMS pour les activités conjointes de lutte contre la tuberculose et le VIH : principes directeurs à l’intention des programmes nationaux et autres partenaires. Genève, Organisation mondiale de la Santé,
    2012 (https://apps.who.int/iris/handle/10665/44814, page consultée le 25 mai 2022).
  125. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 1 December 2021).
  126. Guideline: nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/94836, accessed 6 December 2021).
  127. Research priorities for paediatric tuberculosis. New York: Treatment Action Group, Child and Adolescent TB Working Group; 2018 (https://www.treatmentactiongroup.org/wp-content/uploads/2018/09/Paediatric_TB_ResearchPriorities_10_8_18_Web.pdf, accessed 1 December 2021).

Book navigation